Due to the pharmacological activities of quinazoline and quinazolinone scaffolds, it has
aroused great interest in medicinal chemists for the development of new drugs or drug …

Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …

Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …

Introduction Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed
in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of
care in patients with EGFR mutation-positive (EGFR m+) non-small cell lung cancer …

Abstract In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society
of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in …

Lung cancer is the leading cause of cancer-related mortality and will affect~ 6% of the
population. It is divided into two broad categories, small cell lung cancer and non-small cell …

Squamous cell carcinoma (SCC) of the lung has a markedly different molecular profile to
adenocarcinoma of the lung and remains difficult to treat because of the lack of targeted …

The oncogenic role ERBB2 amplification is well established in breast and gastric cancers.
This has led to the development of a well‐known portfolio of monoclonal antibodies and …

Lung cancer remains the leading cause of cancer-associated mortality worldwide, but with
the emergence of oncogene targeted therapies, treatment options have tremendously …